In 2023, Director Kathi Vidal exercised her authority to conduct sua sponte director reviews of Patent Trial and Appeal Board (PTAB) decisions and addressed a wide range of issues that will impact PTAB practitioners. Many of these sua sponte director reviews related to inter partes review (IPR) institution decisions, which are generally not reviewed at the PTAB and, in nearly all circumstances, are not appealable. These sua sponte director reviews provide important guidance to practitioners on many issues of PTAB practice, including the application of Fintiv, the use of applicant-admitted prior art, and the Advanced Bionics standard.